Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab and Atezolizumab + SBRT in MSS mCRC
NCT06603818Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2025
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Planned start Aug 2025; status: withdrawn.
02
Drugs
tiragolumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06603818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603818.